nach oben

Erschienen in:

01.10.2014 | Original article

High-resolution analysis of DNA copy number alterations in rectal cancer

Correlation with metastasis, survival, and mRNA expression

verfasst von: Jérôme Doyen, MD, Eric Letouzé, Ph.D., Laetitia Marisa, Ph.D., Aurélien de Reyniès, Ph.D., Gérard Milano, Pharm.D., Marie-Christine Etienne-Grimaldi, Pharm.D., Sylviane Olschwang, Ph.D., Jochen Gaedcke, M.D., Ph.D., Michael Ghadimi, M.D., Ph.D., Jean-Pierre Gérard, M.D.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

This study aimed to determine the candidate genes and chromosomal imbalances capable of predicting occurrences of metastasis in patients with rectal cancer.

Patients and methods

Fresh frozen tumor tissues from 80 patients with rectal cancer were prospectively collected and analyzed using Affymetrix HG-U133 Plus 2.0 gene expression arrays and high-resolution Illumina single-nucleotide polymorphism (SNP) arrays. Endpoints of the study were metastasis-free survival (MFS) and cancer-specific survival (CSS).

Results

The median follow-up was 102 months (1–146). Deletions of 8p and 1p36-35 correlated with worse MFS (p = 0.005 and p = 0.01, respectively) and CSS (p = 0.001 and p = 0.01, respectively). Multivariate analysis identified 8p deletion as an independent prognostic factor for MFS (p = 0.04) and CSS (p = 0.003); 97 genes located on the 8p chromosome were significantly underexpressed in tumors with 8p deletion.

Conclusion

This study shows for the first time in rectal cancer an independent correlation of 8p deletion with MFS and CSS and highlights potential new tumor suppressor genes.

Ogino S, Chan AT, Fuchs CS et al (2011) Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 60:397–411PubMedCentralPubMedCrossRef

Halling KC, French AJ, McDonnell SK et al (1999) Microsatellite instability and 8p allelic imbalance in stage b2 and c colorectal cancers. J Natl Cancer Inst 91:1295–1303PubMedCrossRef

TCGA (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337CrossRef

O’Connell MJ, Lavery I, Yothers G et al (2010) Relationship between tumor gene expression and recurrence in four independent studies of patients with stage ii/iii colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 28:3937–3944PubMedCentralPubMedCrossRef

Salazar R, Roepman P, Capella G et al (2011) Gene expression signature to improve prognosis prediction of stage ii and iii colorectal cancer. J Clin Oncol 29:17–24PubMedCrossRef

Russo A, Bazan V, Iacopetta B et al (2005) The tp53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: Influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23:7518–7528PubMedCrossRef

Dvorak J, Sitorova V, Ryska A et al (2012) [prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma]. Strahlenther Onkol 188:833–838PubMedCrossRef

Arribas R, Ribas M, Risques RA et al (1999) Prospective assessment of allelic losses at 4p14–16 in colorectal cancer: two mutational patterns and a locus associated with poorer survival. Clin Cancer Res 5:3454–3459PubMed

Bardi G, Fenger C, Johansson B et al (2004) Tumor karyotype predicts clinical outcome in colorectal cancer patients. J Clin Oncol 22:2623–2634PubMedCrossRef

10.

Hong SP, Min BS, Kim TI et al (2012) The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. Eur J Cancer 48:1235–1243PubMedCrossRef

11.

Frattini M, Balestra D, Suardi S et al (2004) Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 10:4015–4021PubMedCrossRef

12.

Gunderson LL, Jessup JM, Sargent DJ et al (2010) Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol 28:256–263PubMedCentralPubMedCrossRef

13.

Peiffer DA, Le JM, Steemers FJ et al (2006) High-resolution genomic profiling of chromosomal aberrations using infinium whole-genome genotyping. Genome Res 16:1136–1148PubMedCentralPubMedCrossRef

14.

Staaf J, Vallon-Christersson J, Lindgren D et al (2008) Normalization of illumina infinium whole-genome snp data improves copy number estimates and allelic intensity ratios. BMC Bioinformatics 9:409PubMedCentralPubMedCrossRef

15.

Popova T, Manie E, Stoppa-Lyonnet D et al (2009) Genome alteration print (gap): a tool to visualize and mine complex cancer genomic profiles obtained by snp arrays. Genome Biol 10:R128PubMedCentralPubMedCrossRef

16.

Irizarry RA, Bolstad BM, Collin F et al (2003) Summaries of affymetrix genechip probe level data. Nucleic Acids Res 31:e15PubMedCentralPubMedCrossRef

17.

Benjamini Y, Drai D, Elmer G et al (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125:279–284PubMedCrossRef

18.

Grade M, Gaedcke J, Wangsa D et al (2009) Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapy. Cancer Genet Cytogenet 193:19–28PubMedCentralPubMedCrossRef

19.

Ortholan C, Romestaing P, Chapet O et al (2012) Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the lyon r 96–02 randomized trial. Int J Radiat Oncol Biol Phys 83:e165–171PubMed

20.

Glimelius B (2013) Neo-adjuvant radiotherapy in rectal cancer. World J Gastroenterol 19:8489–8501PubMedCentralPubMedCrossRef

21.

El Gammal AT, Bruchmann, Zustin J et al (2010) Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res 16:56–64PubMedCrossRef

22.

Roessler S, Long EL, Budhu A et al (2012) Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 142:957–966e912PubMedCentralPubMedCrossRef

23.

Zhang Y, He X, Liu Y et al (2012) Microrna –320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer. Oncol Rep 27:685–694PubMed

24.

Caglayan AO, Engelen JJ, Ghesquiere S et al (2009) Fluorescence in situ hybridization and single nucleotide polymorphism of a new case with inv dup del(8p). Genet Couns 20:333–340PubMed

Titel: High-resolution analysis of DNA copy number alterations in rectal cancer
Correlation with metastasis, survival, and mRNA expression
verfasst von: Jérôme Doyen, MD
Eric Letouzé, Ph.D.
Laetitia Marisa, Ph.D.
Aurélien de Reyniès, Ph.D.
Gérard Milano, Pharm.D.
Marie-Christine Etienne-Grimaldi, Pharm.D.
Sylviane Olschwang, Ph.D.
Jochen Gaedcke, M.D., Ph.D.
Michael Ghadimi, M.D., Ph.D.
Jean-Pierre Gérard, M.D.
Publikationsdatum: 01.10.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 11/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-014-0659-4

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

ASS schützt nicht vor Brustkrebsrezidiven

02.05.2024 Mammakarzinom Nachrichten

Nützt nichts und ist vielleicht sogar schädlich: In einer Phase-3-Studie konnten täglich 300 mg ASS keine Brustkrebsrezidive bei Frauen vermeiden, die ein hohes Risiko für eine Tumorrückkehr aufwiesen. Tendenziell traten unter ASS sogar häufiger Rezidive auf als unter Placebo.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

High-resolution analysis of DNA copy number alterations in rectal cancer

Correlation with metastasis, survival, and mRNA expression